Ya-Ting Chang1, Chi-Nan Tseng2, Philip Tannenberg2, Linnéa Eriksson2, Ke Yuan3, Vinicio A de Jesus Perez3, Johan Lundberg4, Mariette Lengquist2, Ileana Ruxandra Botusan2, Sergiu-Bogdan Catrina2, Phan-Kiet Tran5, Ulf Hedin2, Karin Tran-Lundmark6. 1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden ya-ting.chang@ki.se. 2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 3. Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, USA Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. 4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Cardiothoracic Surgery, Uppsala University, Uppsala, Sweden. 6. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden Department of Experimental Medical Science, Lund University, Lund, Sweden.
Abstract
AIMS: Excessive vascular cell proliferation is an important component of pulmonary hypertension (PH). Perlecan is the major heparan sulfate (HS) proteoglycan in the vascular extracellular matrix. It binds growth factors, including FGF2, and either restricts or promotes cell proliferation. In this study, we have explored the effects of perlecan HS deficiency on pulmonary vascular development and in hypoxia-induced PH. METHODS AND RESULTS: In normoxia, Hspg2(Δ3/Δ3) mice, deficient in perlecan HS, had reduced pericytes and muscularization of intra-acinar vessels. Pulmonary angiography revealed a peripheral perfusion defect. Despite these abnormalities, right ventricular systolic pressure (RVSP) and myocardial mass remained normal. After 4 weeks of hypoxia, increases in the proportion of muscularized vessels, RVSP, and right ventricular hypertrophy were significantly less in Hspg2(Δ3/Δ3) compared with wild type. The early phase of hypoxia induced a significantly lower increase in fibroblast growth factor receptor-1 (FGFR1) protein level and receptor phosphorylation, and reduced pulmonary artery smooth muscle cell (PASMC) proliferation in Hspg2(Δ3/Δ3). At 4 weeks, FGF2 mRNA and protein were also significantly reduced in Hspg2(Δ3/Δ3) lungs. Ligand and carbohydrate engagement assay showed that perlecan HS is required for HS-FGF2-FGFR1 ternary complex formation. In vitro, proliferation assays showed that PASMC proliferation is reduced by selective FGFR1 inhibition. PASMC adhesion to fibronectin was higher in Hspg2(Δ3/Δ3) compared with wild type. CONCLUSIONS: Perlecan HS chains are important for normal vascular arborization and recruitment of pericytes to pulmonary vessels. Perlecan HS deficiency also attenuates hypoxia-induced PH, where the underlying mechanisms involve impaired FGF2/FGFR1 interaction, inhibition of PASMC growth, and altered cell-matrix interactions. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Excessive vascular cell proliferation is an important component of pulmonary hypertension (PH). Perlecan is the major heparan sulfate (HS) proteoglycan in the vascular extracellular matrix. It binds growth factors, including FGF2, and either restricts or promotes cell proliferation. In this study, we have explored the effects of perlecan HS deficiency on pulmonary vascular development and in hypoxia-induced PH. METHODS AND RESULTS: In normoxia, Hspg2(Δ3/Δ3) mice, deficient in perlecan HS, had reduced pericytes and muscularization of intra-acinar vessels. Pulmonary angiography revealed a peripheral perfusion defect. Despite these abnormalities, right ventricular systolic pressure (RVSP) and myocardial mass remained normal. After 4 weeks of hypoxia, increases in the proportion of muscularized vessels, RVSP, and right ventricular hypertrophy were significantly less in Hspg2(Δ3/Δ3) compared with wild type. The early phase of hypoxia induced a significantly lower increase in fibroblast growth factor receptor-1 (FGFR1) protein level and receptor phosphorylation, and reduced pulmonary artery smooth muscle cell (PASMC) proliferation in Hspg2(Δ3/Δ3). At 4 weeks, FGF2 mRNA and protein were also significantly reduced in Hspg2(Δ3/Δ3) lungs. Ligand and carbohydrate engagement assay showed that perlecan HS is required for HS-FGF2-FGFR1 ternary complex formation. In vitro, proliferation assays showed that PASMC proliferation is reduced by selective FGFR1 inhibition. PASMC adhesion to fibronectin was higher in Hspg2(Δ3/Δ3) compared with wild type. CONCLUSIONS: Perlecan HS chains are important for normal vascular arborization and recruitment of pericytes to pulmonary vessels. Perlecan HS deficiency also attenuates hypoxia-induced PH, where the underlying mechanisms involve impaired FGF2/FGFR1 interaction, inhibition of PASMC growth, and altered cell-matrix interactions. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ke Yuan; Elya A Shamskhou; Mark E Orcholski; Abinaya Nathan; Sushma Reddy; Hiroaki Honda; Vigneshwaran Mani; Yitian Zeng; Mehmet O Ozen; Lingli Wang; Utkan Demirci; Wen Tian; Mark R Nicolls; Vinicio A de Jesus Perez Journal: Circulation Date: 2019-04-02 Impact factor: 29.690
Authors: Ali Keshavarz; Ahmed Alobaida; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan Journal: Mol Pharm Date: 2019-06-27 Impact factor: 4.939